3087 completed, 1229 recruiting, 1198 unknown, 1034 terminated. 3607 Phase 2, 2227 Phase 1, 930 Phase 3, 720 Not applicable, 100 Phase 4.
Follow Bronchial Neoplasms: new trials by email Literature Review of Bronchial Neoplasms trials Research Report on Bronchial Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records Lung Cancer | Not yet recruiting | AstraZeneca | 3000 | 2027-04-01 | 2026-06-02 | |
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2027-03-02 | 2026-10-23 |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Not yet recruiting | Xemed LLC | 10 | 2027-03-01 | 2026-09-01 |
| OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 400 | 2027-02-01 | 2026-10-22 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy Exercise - Non-Small Cell Lung Cancer, Aerobic Exercise | Not applicable | Not yet recruiting | Izmir Bakircay University | 78 | 2027-01-04 | 2026-10-21 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| ctDNA-Guided Intraventricular Therapy for CNS Malignancies CSF ctDNA-Guided Clinical Management - Leptomeningeal Disease, Glioblastoma | Not applicable | Not yet recruiting | Alireza Mansouri | 77 | 2027-01-01 | 2026-07-08 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin (AUC 5 or 6), pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-22 |
| The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer SBRT in stage III NSCLC - Non Small Cell Lung Cancer | Not applicable | Not yet recruiting | All India Institute of Medical Sciences | 20 | 2026-12-19 | 2026-09-24 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 89 | 2026-12-01 | 2026-02-02 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
Showing 20 of 7954. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7065) · Lung Neoplasms (1911) · Small Cell Lung Carcinoma (1200) · Neoplasms (481) · Colorectal Neoplasms (460) · Melanoma (422) · Breast Neoplasms (416) · Neoplasm Metastasis (363) · Ovarian Neoplasms (323) · Squamous Cell Carcinoma of Head and Neck (301) · Carcinoma, Renal Cell (299) · Pancreatic Neoplasms (286) · Stomach Neoplasms (252) · Adenocarcinoma of Lung (238) · Triple Negative Breast Neoplasms (213)
Respiratory Tract Diseases (7913) · Neoplasms by Site (7909) · Respiratory Tract Neoplasms (7905) · Thoracic Neoplasms (7895) · Carcinoma, Bronchogenic (7880) · Lung Diseases (7876) · Neoplasms (7473) · Lung Neoplasms (6043) · Neoplasms by Histologic Type (1493) · Neoplasms, Glandular and Epithelial (1285) · Carcinoma (1044) · Digestive System Diseases (877) · Skin and Connective Tissue Diseases (869) · Digestive System Neoplasms (864)
Carboplatin (952) · Cisplatin (659) · Pemetrexed (638) · Paclitaxel (526) · pembrolizumab (504) · Docetaxel (452) · Gemcitabine (343) · Erlotinib Hydrochloride (308) · Radiotherapy (288) · Nivolumab (270) · Bevacizumab (243) · Etoposide (213) · durvalumab (206) · Drug Therapy (187) · osimertinib (186)
National Cancer Institute (NCI) (205) · AstraZeneca (196) · Eli Lilly and Company (151) · Pfizer (129) · M.D. Anderson Cancer Center (108) · Sun Yat-sen University (102) · Hoffmann-La Roche (101) · Novartis Pharmaceuticals (99) · Bristol-Myers Squibb (97) · Merck Sharp & Dohme LLC (88) · Memorial Sloan Kettering Cancer Center (76) · Boehringer Ingelheim (75) · Alliance for Clinical Trials in Oncology (70) · GlaxoSmithKline (56) · Shanghai Pulmonary Hospital, Shanghai, China (56)
United States (3591) · China (1971) · France (898) · Spain (891) · South Korea (723) · Italy (719) · Canada (695) · Germany (641) · United Kingdom (598) · Australia (525) · Taiwan (514) · Japan (480) · Belgium (450) · Netherlands (446) · Poland (429)
PMID 27130468, PMID 37419867, PMID 40311309, PMID 22586319, PMID 23442309, PMID 27718847, PMID 34870327, PMID 37465924, PMID 42820295, PMID 19692680, PMID 25881079, PMID 26104945, PMID 26291008, PMID 26291023, PMID 27959700, PMID 29658848, PMID 30280641, PMID 33337539, PMID 35537408, PMID 38642841, PMID 39113428, PMID 39462179, PMID 25175099, PMID 25436806, PMID 25490004, PMID 25589191, PMID 26028407, PMID 26051236, PMID 26768165, PMID 26823294, PMID 28445469, PMID 28472437, PMID 28501139, PMID 28885881, PMID 29290251, PMID 29658856, PMID 30207593, PMID 30419929, PMID 31590988, PMID 32736936, PMID 33096027, PMID 33241650, PMID 34405547, PMID 34408488, PMID 34409776, PMID 35576956, PMID 35930972, PMID 36184621, PMID 37934000, PMID 38468440
2023 (133), 2017 (62), 2016 (59), 2018 (59), 2019 (58), 2025 (55), 2014 (49), 2015 (48), U10CA031946 (36), U10CA032102 (26), P30CA033572 (23), 2009 (21), U10CA180888 (21), 2008 (19), P30CA012197 (19)